Publications

International journal of cancer

Early Cessation of Adjuvant Anti-PD-1 Therapy in Stage III and IV Melanoma.

09-09-2026

Lancet (London, England)

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

29-08-2026

European journal of cancer (Oxford, England : 1990)

Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy.

26-08-2026

Clinical cancer research : an official journal of the American Association for Cancer Research

Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

03-08-2026

European journal of cancer (Oxford, England : 1990)

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

26-07-2026

Cancer treatment and research communications

Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.

19-07-2026

Transplantation and cellular therapy

Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles.

01-07-2026

European urology open science

Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141].

01-07-2026

Journal for immunotherapy of cancer

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

25-06-2026

European journal of cancer (Oxford, England : 1990)

AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response.

25-06-2026

The Lancet regional health. Europe

Advances in cell therapy for solid tumours: European perspective and future directions.

01-05-2026

Nature medicine

Publisher Correction: Clinical development of cancer vaccines.

01-04-2026

Journal for immunotherapy of cancer

Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data.

03-03-2026

Nature medicine

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

01-03-2026

Nature medicine

Clinical development of cancer vaccines.

01-03-2026

European journal of nuclear medicine and molecular imaging

[¹⁸F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.

01-03-2026

Nature communications

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy.

05-02-2026

European urology open science

Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials.

01-01-2026

Nature

Tumour-reactive heterotypic CD8 T cell clusters from clinical samples.

01-01-2026

Nature medicine

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

01-12-2025

Key Publication

Nature

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.

01-12-2025

JAMA oncology

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma.

01-12-2025

Journal for immunotherapy of cancer

Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better?

28-11-2025

European journal of cancer (Oxford, England : 1990)

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

17-11-2025

EClinicalMedicine

Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study.

01-11-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial.

01-10-2025

Key Publication

Nature reviews. Nephrology

Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors.

01-10-2025

European journal of cancer (Oxford, England : 1990)

The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma.

09-09-2025

Nature medicine

Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

01-09-2025

Immuno-oncology technology

Properties of CD8 T-cell-recognized neoantigens in different tumor types.

01-09-2025

Med (New York, N.Y.)

Advances in TIL therapy: Expanding the horizons beyond melanoma.

08-08-2025

Clinical nuclear medicine

Imaging Proliferation of Stage IV Cutaneous Melanoma With 18 F-FLT PET/CT : A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?

01-08-2025

Journal of the American Medical Informatics Association : JAMIA

Multimodal integration of longitudinal noninvasive diagnostics for survival prediction in immunotherapy using deep learning.

01-08-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

01-08-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

01-07-2025

Nature medicine

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.

01-07-2025

Trends in cancer

Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?

01-07-2025

Scientific reports

Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors.

01-07-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

01-07-2025

British journal of cancer

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

01-07-2025

European journal of cancer (Oxford, England : 1990)

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

18-06-2025

Cancer cell

Learning the language of T cell receptors through large-scale screening.

09-06-2025

European journal of cancer (Oxford, England : 1990)

Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial.

03-06-2025

British journal of cancer

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

01-06-2025

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities.

01-06-2025

Journal of the National Cancer Institute

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study.

01-06-2025

The British journal of surgery

Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.

31-05-2025

EJNMMI research

Metabolic parameters on baseline and early [¹⁸F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma.

28-05-2025

European journal of cancer (Oxford, England : 1990)

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.

02-05-2025

Medical decision making : an international journal of the Society for Medical Decision Making

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.

01-04-2025

Early Cessation of Adjuvant Anti-PD-1 Therapy in Stage III and IV Melanoma.

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy.

Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.

Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles.

Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141].

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response.

Advances in cell therapy for solid tumours: European perspective and future directions.

Publisher Correction: Clinical development of cancer vaccines.

Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data.

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

Clinical development of cancer vaccines.

[18F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy.

Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials.

Tumour-reactive heterotypic CD8 T cell clusters from clinical samples.

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma.

Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better?

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study.

Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial.

Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors.

The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma.

Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Properties of CD8 T-cell-recognized neoantigens in different tumor types.

Advances in TIL therapy: Expanding the horizons beyond melanoma.

Imaging Proliferation of Stage IV Cutaneous Melanoma With 18 F-FLT PET/CT : A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?

Multimodal integration of longitudinal noninvasive diagnostics for survival prediction in immunotherapy using deep learning.

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.

Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?

Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors.

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Learning the language of T cell receptors through large-scale screening.

Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial.

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities.

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study.

Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.

Metabolic parameters on baseline and early [18F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma.

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.

This site uses cookies

[¹⁸F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.

Metabolic parameters on baseline and early [¹⁸F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma.